Verisante Technology, Inc. announced that it has entered into a collaboration with the BC Cancer Agency and Imperial College Healthcare NHS Trust to develop a new application for the company's exclusively licensed platform technology. Imperial College Healthcare NHS Trust will be using Verisante's laser Raman system in a study to determine if the system is able to assist in ascertaining the margins between tumour and normal brain tissue. Verisante is providing Imperial College Healthcare NHS Trust with a Raman system.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 USD | +117.39% |
|
0.00% | +49,900.00% |
1st Jan change | Capi. | |
---|---|---|
+49,900.00% | 220K | |
+3.26% | 209B | |
+6.55% | 183B | |
+31.66% | 158B | |
+34.32% | 114B | |
+5.13% | 67.29B | |
+19.33% | 54.83B | |
-3.30% | 46.88B | |
-4.84% | 38.58B | |
+3.83% | 36.65B |
- Stock Market
- Equities
- VRSEF Stock
- News Verisante Technology Inc.
- Verisante Technology, Inc. Enters into Collaboration with BC Cancer Agency and Imperial College Healthcare NHS Trust to Develop New Application for its Exclusively Licensed Platform Technology